Gavi and Geri fertility technologies secure CE Mark- Merck KGaA + Genea Biomedx
Merck KGaA announced that the two innovative fertility technologies Gavi and Geri have achieved CE Mark certification. The grant of regulatory clearance allows Gavi and Geri to be made available for sale in the European Union. The technologies have been developed through the fertility know-how of Genea Biomedx's parent company Genea, and are designed to provide solutions to some of the challenges involved in successful fertility treatment.
Genea Biomedx specializes in technology to improve the process of in vitro fertilization (IVF). Gavi is the first automated vitrification instrument. This is used to preserve human egg cells or embryos by cooling them to subzero temperatures. The automation is intended to help ensure consistent results in blastocyst vitrification. Geri is a benchtop incubator with individually controlled incubation chambers per patient to minimize disruption. It also has a time-lapse camera to monitor embryo development. Genea Biomedx is the technology arm of Genea, a group of pioneering Australian fertility centers.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins